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Introduction: The neurotrophic drug Cerebrolysin is composed of low-molecular-weight
peptides and amino acids and has been shown to have neuroprotective and neuroplastic
properties. Cerebrolysin has been reported to promote the recovery of motor functions
in central nervous system disorders; however, the effects on the consciousness
improvements in post-stroke patients have not yet been studied extensively. Therefore,
we aimed to examine the effectiveness of Cerebrolysin on improving the consciousness
level of stroke patients with minimally conscious state (MCS).
Materials and Methods: In this retrospective study we included ischemic and/or
hemorrhagic stroke patients with MCS according to the Coma Recovery Scale-Revised
(CRS-R), who were admitted to our hospital between 2014 and 2017. All patients
received comprehensive rehabilitation therapy including physical and occupational
therapy. We compared patients treated with Cerebrolysin against patients who did not
receive Cerebrolysin. Patients were included in the verum group if they received 10mL
of Cerebrolysin IV for at least 20 days. CRS-R scores were assessed at admission
and discharge.
Results: Of 1,531 patients screened, 75 were included in the study (Cerebrolysin,
n = 43; control, n = 32). Baseline characteristics were similar between groups. At
discharge, ∼2 months after onset of stroke, Cerebrolysin-treated patients improved
significantly in the CRS-R (p= 0.010) after adjustment for confounders using linear mixed
model (LMM), especially in the Oromotor (p = 0.003) and Arousal subscales (p = 0.038).
No safety issues were observed.
Conclusion: This retrospective study suggests that Cerebrolysin may improve the level
of consciousness in stroke patients with MCS, which should be further investigated in a
well-designed, double-blind, placebo-controlled, randomized trial.
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INTRODUCTION
Stroke is the second leading cause of death in the world.
About 14 million incidences of first-time strokes worldwide were
reported in 2016 with 5.7 million deaths (1, 2), and stroke-
related diseases, disorders, and pre-mature deaths are expected
to double by 2035 (3). The social cost to the US economy due
to stroke in the period from 2005 to 2050 is estimated at $2.2
trillion (4). Considering the tremendous socioeconomic burden,
which is expected to further increase due to the continuous
increase in life expectancy and proportion of elderly people, it
is important to prevent or reduce stroke-related complications
as early as possible. Neurologic complications of stroke include
cerebral edema, hemorrhagic transformation, epilepsy, recurrent
stroke, and consciousness disturbance. Though not always life-
threatening, these can lead to delayed rehabilitation, long-
term hospitalization, poor functional outcome, and increased
health care costs. According to various stroke registry data,
4–38% of patients with stroke experience a decrease in the
consciousness level or mental status (5). Studies have shown that
there are possible risk factors for impairment of consciousness
after stroke including age, sex, previous stroke history, atrial
fibrillation, diabetes mellitus, alcohol consumption, stroke
severity, anatomical location of injury site, massive cerebral
infarct, and multiple brain infarcts (6).
Several reports have suggested that administration of growth
hormones and neurotrophic factors such as brain-derived
neurotrophic factor (BDNF), glial cell line-derived neurotrophic
factor (GDNF), nerve growth factor (NGF), and ciliary
neurotrophic factor (CNTF) may be associated with improved
nerve regeneration after injury of the central nervous system
(7). Cerebrolysin (EVER Neuro Pharma GmbH, AUSTRIA) is
composed of low-molecular-weight peptides and amino acids
and has been shown to exert neuroprotective and neurotrophic
effects similar to endogenous neurotrophic factors (8).
Previous clinical trials in acute stroke with more than 1,500
patients enrolled have confirmed the safety and good tolerability
of Cerebrolysin (9, 10). The CASTA study showed a significant
decrease in mortality and disability as compared to placebo in
severely affected patients (NIHSS > 12) (11). A recent meta-
analysis of nine randomized controlled trials with Cerebrolysin
has confirmed a clinically relevant and statistically significant
effect of the drug in improving neurological function and clinical
outcome after stroke (12).
Although there is robust evidence for Cerebrolysin to improve
neuronal recovery after brain injuries, the effect of the drug
on recovery of consciousness after severe stroke has not yet
been studied. Accordingly, this retrospective study aimed to
investigate the effects of Cerebrolysin on the recovery of
consciousness in post-stroke patients with minimally conscious
state (MCS).
MATERIALS AND METHODS
Enrolment Criteria
In our study, we included adult, male, and female patients
- with confirmed stroke
- who met MCS criteria according to the Coma Recovery Scale-
Revised (CRS-R) (13)
- treated with Cerebrolysin for at least 20 days; Cerebrolysin
was administered intravenously at a daily dosage of 10ml;
patients who did not receive Cerebrolysin were allocated to
the control group.
- with complete medical charts and CRS-R scores assessed at
admission and discharge.
We did not include patients
- with a diagnosis of brain lesions other than stroke, such as
traumatic brain injury (TBI) or hypoxic brain injury (HBI)
- with a pre-existing or active major neurological disease
including TBI
- with progressive or unstable stroke
- with a history of significant alcohol or drug abuse and
advanced liver, kidney, cardiac, or pulmonary disease
(abnormal values of liver enzymes: total serum bilirubin >4
mg/dl, alkaline phosphatase > 250 U/L, SGOT/AST > 150
U/L, SGPT/ALT> 150 U/L, creatinine> 3.5 mg/dl)
- with a medical diagnosis of an expected survival of<1 year
- under treatment with traditional oriental medicine,
vasodilators such as naftidrofuryl, cinnarizine, flunarizine,
or nimodipine
- with any condition that would represent a contraindication
for Cerebrolysin
- with a history of Cerebrolysin treatment
- who participated in other therapeutic studies.
All caregivers were informed about the risk and benefit of
Cerebrolysin administration including possible serious adverse
effects when the patient met the MCS criteria and then they
decided whether to administer the Cerebrolysin to patients. The
control group consisted of patients whose caregivers decided not
to administer it to the patients.
The protocol of this study was approved by the Institutional
Review Board (IRB) of the Yonsei University.
Statistical Analysis
Medical record data were entered into a computer database and
further analyzed with the Statistical Package for Social Sciences
(SPSS Inc., Chicago, IL, USA) version 25. Data are expressed as
mean ± standard deviation (SD), median ± interquartile range
(IQR), and proportions, depending on the type of distribution
of data. To compare baseline demographics and clinical data, χ2
tests and Fisher’s exact tests were used for categorical variables
and independent t-test was used for the parametric continuous
variables, respectively. The variables that are already assumed to
be normally distributed generally in the population group were
regarded as parametric variables because the number of patients
in each group exceeded 30. Paired t-test was used to compare
parametric variables within the groups. The linear mixed model
(LMM) was also used, setting the CRS-R total and subscores at
admission and discharge as dependent variables and the other
possible effectors as factors, to adjust the effects of covariates.
Simple and multiple stepwise regression analyses were also used
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FIGURE 1 | Flow chart of inclusion and disposition of subjects.
to determine the effects of covariates. A two-tailed p < 0.05 was
considered statistically significant.
RESULTS
A total of 1,531 patients were identified through medical records
review. Of these, 75 patients were included in our study, of
which 43 (57.3%) patients were allocated to the Cerebrolysin
group and 32 (42.7%) patients were allocated to the control
group (Figure 1).
The age of the patients was 69.0 ± 14.9 (range, 23 to 93)
years; 46 (61.3%) were males and 29 (38.7%) were females.
Stroke was caused by intracerebral hemorrhage (n= 26), cerebral
infarction (n = 45), and cerebral infarction with hemorrhage
(n = 4). Further baseline characteristics are summarized in
Table 1. There was no statistically significant difference in the
baseline characteristics.
In both groups, CRS-R total scores increased significantly
between admission and discharge (p ≤ 0.001; Figure 2) by 4.2
points in the Cerebrolysin group and 2.3 points in the control
group. In the inter-group analysis using LMM, the increase in
the total score of CRS-R was statistically significantly higher in
the Cerebrolysin group by the interaction of time and the use of
Cerebrolysin (p= 0.010) after adjusting for age, sex, recurrence of
stroke, length of hospital stay, duration from onset, concomitant
use of neurostimulants, etiology of stroke, location of lesions,
and laterality of lesions. CRS-R subscale analyses also showed
higher improvement with use of Cerebrolysin in the Oromotor
function (p = 0.003) and Arousal (p = 0.038; Table 2) after
adjustment. A trend in favor of Cerebrolysin was also seen in
the visual function subscale (p = 0.061). In the other subscales
(auditory function, motor function, and communication), the
improvement from admission to discharge was descriptively
greater in the Cerebrolysin group. The use of Cerebrolysin was
the only variable that showed significant explanatory power by
multiple stepwise regression (p = 0.010) and other variables had
no significant effects (Table 3).
None of the patients experienced a serious adverse reaction
(SAE) known to be related to the administration of Cerebrolysin.
DISCUSSION
Our retrospective study showed that Cerebrolysin significantly
improved the level of consciousness of patients with MCS after
acute stroke when compared to the control group. In our
opinion, the improvement in the CRS-R score as observed in
the Cerebrolysin group is clinically relevant and almost twice as
high as in the control group. The increase in the total score of
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TABLE 1 | Baseline characteristics of subjects.
Characteristic Cerebrolysin
group
(n = 43)
Control group
(n = 32)
p-value
Age (years) 69.0 ± 15.4 68.7 ± 14.5 0.995
Sex (male/female) 23/20 23/9 0.106
Recurrence (first-ever/recurrent) 34/9 24/8 0.677
Etiology
(infarction/hemorrhage/both)
18/19/6 19/9/4 0.296
CRS-R total scores at admission 13.1 ± 3.9 14.3 ± 3.1 0.151
Median CRS-R scores at admission
(interquartile range)
Total 14 (10.00–16.00) 15 (11.25–16.75)
Auditory 2 (2.00–3.00) 2 (2.00–3.00)
Visual 3 (2.00–4.00) 3 (2.00–4.00)
Motor 5 (3.00–5.00) 5 (2.25–5.00)
Oromotor 1 (1.00–2.00) 2 (1.00–2.00)
Communication 1 (0.00–1.00) 1 (0.00–1.00)
Arousal 2 (2.00–2.00) 2 (2.00–3.00)
Length of hospital stay (days) 50.1 ± 13.7 64.0 ± 45.0 0.106
Values are means ± standard deviation (SD). CRS-R indicates JFK Coma Recovery
Scale-Revised.
CRS-R was statistically significantly higher in the Cerebrolysin
group by the interaction of time and the use of Cerebrolysin
analysis even after adjustment for confounders using LMM. The
use of Cerebrolysin was also significant in multiple regression
analyses, and none of the potential confounding parameters
had a significant influence on the outcome. Thus, Cerebrolysin
treatment was the only effective factor in improving the CRS-
R scores irrespective of age, sex, laterality of lesions, location of
lesions, and the etiology of the stroke. We therefore consider our
results very robust and interesting, and the results are also in line
with a previous clinical Cerebrolysin study that showed improved
cognitive functions in patients after ischemic stroke, albeit in a
less affected stroke population (9).
A possible explanation of our findings is that treatment with
Cerebrolysin might have increased the level of neurotrophic
factors like BDNF. The brain of an individual with higher BDNF
is more resistant to damage; thus, patients with higher BDNF
levels may have higher capacity for consciousness recovery (14).
Positive associations between plasma BDNF levels and cognitive
functions like learning capacity, verbal delayed memory, abstract
verbal reasoning, and processing speed were also shown in first
episode psychosis (FEP) (15).
Furthermore, Cerebrolysin has been shown to interfere in
several steps of the ischemic cascade and to promote neuroplastic
processes in vivo and in vitro (16, 17), which also might have
contributed to the observed improvement.
There are two representative circuits involved in the
level of consciousness: the reticular activating system (RAS)
and thalamocortical loops (TCL). Brain damage can result
in dysfunctions of these neuronal circuits that interfere
with consciousness (18). Consciousness depends on nerve
impulses that can be influenced by neurotransmitters
FIGURE 2 | Changes of JFK-CRS total scores in both groups from admission
to discharge. *p < 0.05 comparing CRS-R total scores at discharge with
scores at admission in each group by paired t-test, and comparing
Cerebrolysin group vs. control group over time by linear mixed model (LMM).
and their homeostasis. The most abundant and universal
neurotransmitters in the brain are amino acids and monoamines.
These include the oxygen-based amino acids such as glutamate
and γ-aminobutyric acid (GABA), and monoamines such
as dopamine, noradrenalin, adrenaline, and serotonin (19).
Lack of awareness in the vegetative state (VS) and MCS is
presumed to continue when restoration of neurotransmitter
reserves remains incomplete in parts of the brain (20). Therefore,
neurotransmitters like the oxygen-based amino acids and
monoamines have been suggested as potential pharmacological
agents for improvement of consciousness (19). In an open-label
study performed with oral 10-mg zolpidem in 60 patients who
suffered from impairment of consciousness, 20% of them showed
improved behavior and/or CRS-R scores 1 h after administration,
but significant improvements were observed in one patient only
(use of functional objects) (21).Methylphenidate has been known
to improve the action of catecholamines in the brain by blocking
dopamine and norepinephrine reuptake by neurons. An effect of
methylphenidate on the recovery of consciousness early in the
post acquired brain injury period has previously been reported
(22). Amantadine is one of the most commonly prescribed
medications for patients with consciousness disturbance after
brain injury (23) acting as indirect dopamine agonist with
an N-methyl-D-aspartate antagonist (24). Amantadine was
effective in three randomized trials dealing with patients
suffering from consciousness disturbances after traumatic
brain injuries (25–27). However, most of these studies
were related to disturbances of consciousness after TBI
rather than stroke. However, in these studies, no further
improvement of the consciousness level was observed after
drug discontinuation.
In our study, we did not find significant effects of
dopaminergic drugs, methylphenidate, and acetylcholine esterase
inhibitors. It is in line with a recent multicenter study to identify
predictors of consciousness changes in 364 patients with disorder
of consciousness after brain damage (28). They revealed that
physical and cognitive treatments, age, and use of psycholeptic
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TABLE 2 | Comparison of CRS-R scores at admission and discharge between Cerebrolysin and control groups.
CRS-R scores Cerebrolysin group
(n = 43)
Control group
(n = 32)
Unadjusted
p-value
Adjusted
p-value‡
Admission Discharge Admission Discharge
Total score 13.1 ± 3.9 17.3 ± 4.0† 14.3 ± 3.1 16.5 ± 4.1† 0.010* 0.010*
Subscores
Auditory 2.2 ± 0.8 2.9 ± 1.0† 2.4 ± 0.9 2.8 ± 1.0† 0.116 0.116
Visual 2.8 ± 1.1 3.9 ± 0.9† 3.2 ± 1.0 3.8 ± 1.1† 0.061 0.061
Motor 4.0 ± 1.5 4.9 ± 1.2† 4.0 ± 1.5 4.6 ± 1.6† 0.300 0.300
Oromotor 1.5 ± 0.6 2.1 ± 0.8† 1.8 ± 0.6 1.9 ± 0.7 0.003* 0.003*
Communication 0.5 ± 0.5 1.0 ± 0.7† 0.7 ± 0.5 1.0 ± 0.6† 0.351 0.351
Arousal 2.1 ± 0.7 2.5 ± 0.6† 2.3 ± 0.5 2.4 ± 0.5 0.038* 0.038*
Values are means ± standard deviation (SD). CRS-R indicates Coma Recovery Scale-Revised.
Bold values indicates *p < 0.05 comparing Cerebrolysin group vs. control group over time by linear mixed model (LMM).
†
p < 0.05 comparing subscores at discharge with scores at admission in each group by paired t-test.
‡Adjustment for confounders including age, sex, recurrence of stroke, length of hospital stay, duration from onset, concomitant use of neurostimulants, etiology of stroke, location of
lesions, and laterality of lesions was done using LMM.
TABLE 3 | Results of simple and multiple regression analyses of CRS-R
improvement in all subjects.
Variables Simple regression Multiple stepwise
regression
β Coefficient p-value β Coefficient p-value
Age −0.024 ± 0.026 0.353
Sex (male) 0.241 ± 0.792 0.762
Recurrent stroke −0.566 ± 0.920 0.540
Length of hospital
stay
−0.022 ± 0.012 0.072
Duration from onset −0.004 ± 0.002 0.078
Use of
Cerebrolysin®
−1.975 ± 0.746 0.010§ −1.975 ± 0.746 0.010§
Dopaminergic drugs −0.283 ± 0.859 0.743
Methylphenidates 0.570 ± 0.885 0.522
Acetylcholinesterase
inhibitors
−1.363 ± 0.756 0.076
Etiology of stroke
Ischemia Reference
Hemorrhage 1.098 ± 0.829 0.190
Both −0.473 ± 1.180 0.690
Location of lesions
Supratentorial Reference
Infratentorial −0.630 ± 1.106 0.571
Both 0.518 ± 1.268 0.684
Laterality of lesions
Right Reference
Left 0.897 ± 1.771 0.614
Bilateral 1.345 ± 1.763 0.448
Values are means ± standard error of the mean (SEM). CRS-R indicates Coma
Recovery Scale-Revised.
Bold values indicates §p < 0.05 according to linear regression analysis.
drugs were the significant predictors, but the use of antiparkinson
drugs, psychoanaleptics, and muscle relaxants was not.
This study showed that the Oromotor and Arousal subscores
were improved especially among the subscores. However, the
underlying molecular mechanisms are still unclear. Based on
neuroanatomy related to consciousness, we further suggest a
hypothesis on underlying mechanism about the statistically
significant difference in the amount of Arousal subscores’
increments, which shows wakefulness, an important element of
consciousness. RAS spreads from the midbrain with ascending
projections to the basal forebrain complex (BFC) through
two pathways, dorsally via the thalamus and ventrally via the
hypothalamus (19). Previous studies have shown that NGF,
one of the components of Cerebrolysin, plays an important
role in survival and function of cholinergic neurons in the
BFC (29). The BFC is a region of the brain responsible for
attention, arousal, motivation, memory, and consciousness. In
particular, NGF is fundamental for the functional integrity of
cholinergic neurons in the central nervous system (30) and
it also plays a role in regulating the phenotypic features of
the noradrenergic nuclei of hypothalamus (31, 32). Thus, NGF
contained in Cerebrolysin may have had a positive impact on
the improvement of consciousness levels though enhancing two
important components of the RAS circuit by upregulating the
phenotypic features of the noradrenergic nuclei of hypothalamus
and the function of cholinergic neurons of BFC. Although the
level of consciousness may have been enhanced through the role
of NGF, further basic research is needed to explain the underlying
therapeutic mechanism of Cerebrolysin.
The findings of the present study have several limitations like
the retrospective design and no control of concomitant use of
neurostimulants at admission.
Even though this study showed that Cerebrolysin was effective
in improving the level of consciousness after adjustment for
confounding factors and multiple regression analysis showed
no significant association of other drugs with the consciousness
outcomes, we cannot fully exclude possible impacts since
it was not possible to control potential interactions of the
drugs or the impact of the dosage. In addition, the level of
caregivers’ attention to patient care and/or the patient’s current
severity might have affected the assignment to the control
or experimental group, which could have acted as selection
bias. Besides, patients diagnosed as VS were not included in
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the study because their number was too small to represent
characteristics of VS patients. Furthermore, due to the small
number of enrolled patients, the multivariate model might not
have had enough power to adjust for more complex variables.
Therefore, in future studies, the enrollment of more patients
with longer follow-up periods should be considered. Also, we
recruited only patients who had been given Cerebrolysin for
20 days or more and who had no contraindications to the
drug. Therefore, we were not able to fully determine the safety
profile of the drug or a dose relationship of the response
to treatment.
In the future, prospective double-blind, randomized
controlled studies including vs. patients controlling confounding
factors mentioned above will be needed, and neuroimaging
techniques such as resting state functional magnetic resonance
imaging or positron emission tomography brain scan will be
helpful in explaining the underlying mechanisms.
Since previous studies did not assess the level of consciousness
as an outcome parameter, our results are therefore valuable
in presenting a different view of the therapeutic value of
Cerebrolysin. We consider our results very promising, in
particular because we were able to achieve a significant
improvement of the state of consciousness in a population of
patients where meaningful clinical effects are rarely seen in
clinical practice.
CONCLUSION
The results of this study suggest that Cerebrolysin may have a
positive effect on improving the level of consciousness in patients
with post-stroke MCS. No. safety issues were observed for
Cerebrolysin; thus, further investigations might be considered,
which could include imaging techniques to examine also changes
in functional connectivity and brainmetabolism by Cerebrolysin.
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